Paper of the Month

For November 2020, we have selected: Wang Z. et al. Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease. JAMA Neurol 2020;e203311. doi: 10.1001/jamaneurol.2020.3311. Online ahead of print.

For October 2020, we have selected the following Covid-19 paper: Hernández-Fernández F. et al. Cerebrovascular disease in patients with COVID-19: neuroimaging, histological and clinical description. Brain 2020 Jul 9;awaa239. doi: 10.1093/brain/awaa239. Online ahead of print.

For October 2020, we have selected the following Research paper: Livingston G. et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission.

For September 2020, we have selected: The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report.

For September 2020, we have selected two complementary papers.

For August 2020, we have selected Turner R.S. et al. “Nilotinib Effects on Safety, Tolerability,and Biomarkers in Alzheimer’s Disease” Annals of Neurology 2020;88:183–194. doi: 10.1002/ana.25775. Epub 2020 May 28.

For August 2020, we have selected Rogers J.P. et al. “Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic” Lancet Psychiatry 2020; 7:611-627.

For July 2020, we have selected: Yang P. et al. Endovascular Thrombectomy with or without Intravenous Alteplase in Acute Stroke

For June 2020, we have selected: Mao L. et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China JAMA

For May 2020, we have selected: Lechien JR, Chiesa-Estomba CM, De Siati DR et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild‑to‑moderate forms of the coronavirus disease (COVID‑19): a multicenter European study.

In these troubled times, our Paper of the Month for April is: Grasselli G, Pesenti A, Cecconi M. Critical care utilization for the Covid-19 outbreak in Lombardy, Italy: Early experience and forecast during an emergency response.

For March 2020, we have selected: Olanow et al, Apomorphine sublingual film for off episodes in Parkinson’s disease: a randomised, double-blind, placebo-controlled phase 3 study. Lancet Neurology; 19: 135-44.

For February 2020, we have selected: Kleine-Borgmann J, Schmidt K, Hellmann A, Bingel U. Effects of open-label placebo on pain, functional disability, and spine mobility in patients with chronic back pain: a randomized controlled trial.

For January 2020 we have selected Kapur J et al., Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus,

For December 2019, we have selected: Cree et al., Inebilizumab for the treatment of neuromyelitis optica (N-MOmentum): a double-blind, randomised placebo-controlled  phase 2/3 trial Lancet 2019 Epub ahead of print Sept 5.